And each year, MD+DI editors take the time to look at the companies and segments of the industry that have the biggest gains and the biggest losses. This time, we’re looking at the biggest winners in ...

Montagu and Kohlberg will acquire Teleflex Medical OEM for $1.5B in a carve-out deal, closing in 2026. Private equity firms ...

Medical LSR molding simulation prevents defects, reduces costs, and ensures regulatory compliance for device manufacturers.

Alcon raises its Staar Surgical bid to $1.6B amid shareholder opposition, with a December 19 vote scheduled for acquisition.

Surgical lasers must ensure clear pedal selection, instant shutoff on changes, and robust testing to prevent unintended ...

A 1999 MD+DI editorial identified which factor as most critical for quality and productivity success in the medical device industry?

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

In Medtronic’s case specifically, the EY authors write, the company reported that its ability to predict and modulate supply ...

An FDA panel unanimously rejected J&J's V-Wave Ventura heart shunt, citing risks outweighing benefits despite safety data.

This week in Pedersen's POV, MD+DI Senior Editor Amanda Pedersen explores the medtech industry's most pressing needs as 2025 ...

Stereotaxis's CEO, David Fischel, speaks about the company moving from the brink of bankruptcy to paying off its debt and becoming successful.

During the early stages of the pandemic, SPAC mergers were the route that many medtech companies took to go public.